Posted On: 11/08/2014 9:46:45 AM
Post# of 30067
Re: biotechexpert #10237
***** Only 7 weeks remaining with 12 milestone deliverables *****
He sure as chit does - lets count em, shall we?
2b.) LymPro - incl. patients w/ mild AZ, enrollment 68 patient LP-002 exten. (est. 4Q14)
03.) LymPro - JV Partnership Agreement (end of summer / rev. to est. 4Q14)
05.) LymPro - Partner valid. of APP & CLIA cert. (est. 4Q14)
06.) Eltoprazine - 200 patient Ph. 2b trial PD-LID (est. 4Q14)
07.) Eltoprazine - US IND filed & apvd. for PD-LID (est. 4Q14)
08.) MANF - Ophthalmological ear toxicology complete data sets (est. 4Q14)
10.) MANF / GDNF - Renishaw CED Ph. 2B test trial results (est. 4Q14)
12.) MANF OIS - Ocular Ischemic Syndrome - ODD applic. filed (est. 4Q14)
13.) MANF DB-1 Wolframs - Retinal eye data test results (est. 4Q14)
14.) MANF DB-1 Wolframs - orphan potential (est. 4Q14)
15.) MANF - Good Mfg. Practices (GMP) for 1st in-man studies (est. 4Q14)
25.) NASDAQ up-listing - (est. 4Q14)
***** Note: all above items were abstracted from the 4 following recent sources: *****
a.) AMBS Chairmans Blog, dated 8/10/14
b.) Crystal Research Co. Report, dated 9/8/14
c.) SEC 8-K Filing, dated 10/10/14
d.) 10/09 PR – Item #2b rev.
Read More: http://investorshangout.com/post/view?id=2160...z3IUMb7rfg
Quote:
"Gerald has alot of ground to cover before EOY"
He sure as chit does - lets count em, shall we?
2b.) LymPro - incl. patients w/ mild AZ, enrollment 68 patient LP-002 exten. (est. 4Q14)
03.) LymPro - JV Partnership Agreement (end of summer / rev. to est. 4Q14)
05.) LymPro - Partner valid. of APP & CLIA cert. (est. 4Q14)
06.) Eltoprazine - 200 patient Ph. 2b trial PD-LID (est. 4Q14)
07.) Eltoprazine - US IND filed & apvd. for PD-LID (est. 4Q14)
08.) MANF - Ophthalmological ear toxicology complete data sets (est. 4Q14)
10.) MANF / GDNF - Renishaw CED Ph. 2B test trial results (est. 4Q14)
12.) MANF OIS - Ocular Ischemic Syndrome - ODD applic. filed (est. 4Q14)
13.) MANF DB-1 Wolframs - Retinal eye data test results (est. 4Q14)
14.) MANF DB-1 Wolframs - orphan potential (est. 4Q14)
15.) MANF - Good Mfg. Practices (GMP) for 1st in-man studies (est. 4Q14)
25.) NASDAQ up-listing - (est. 4Q14)
***** Note: all above items were abstracted from the 4 following recent sources: *****
a.) AMBS Chairmans Blog, dated 8/10/14
b.) Crystal Research Co. Report, dated 9/8/14
c.) SEC 8-K Filing, dated 10/10/14
d.) 10/09 PR – Item #2b rev.
Read More: http://investorshangout.com/post/view?id=2160...z3IUMb7rfg
(0)
(0)
